Special guest Adam Feuerstein joins hosts in discussing Q1 earning reports, ONO's acquisition of Deciphera, X4's FDA approval, COVID fatigue, Biden’s Cancer Moonshot, drugmaker lawsuits, FTC targeting 'junk' patents, and emerging safety concerns in MorphoSys' study. Other topics include BridgeBio spinning out an oncology company, US government reclassifying marijuana, and more industry insights.
BridgeBio shifts focus to oncology with new subsidiary, emphasizing novel drug candidates like G12C KRAS inhibitor.
FTC challenges patents in Orange Book, aiming to reclassify marijuana for medical research advancements.
Deep dives
Bridge Bio Spin's Out Oncology Company
Bridge Bio announced a $200 million private financing and corporate divestiture of its oncology subsidiary, pivoting towards a new company called Bridge Bio Oncology Therapeutics. This move allows them to focus on new drug candidates like a G12C KRAS on inhibitor, a PI3K alpha, and a G12C multi-inhibitor to enter the oncology space.
X4 Receives FDA Approval for Wim Syndrome Drug
X4 Pharmaceuticals obtained FDA approval for Zorileum-G, a drug indicated for Wim Syndrome. While the approval is a significant milestone, the market reaction was mixed, reflecting anticipation for the chronic neutropenia market, which is still in the future for X4.
FTC Challenges Orange Book Patents
The FTC is challenging the listing of patents on the Orange Book, aiming to reclassify marijuana from schedule one to schedule three drug. This move could facilitate more medical research and utilization of marijuana for medicinal purposes, paving the way for further developments in the industry.
On this week’s Biotech Hangout, hosts Daphne Zohar, Eric Schmidt, Yaron Werber and Luba Greenwood are joined by special guest and STAT reporter, Adam Feuerstein. The episode kicks off with the hosts sharing their thoughts on industry sentiment and some of the revealing trends in the week’s Stifel report before diving into Q1 earning reports from Ascendis, Amgen and SpringWorks. The hosts talk about ONO’s acquisition of Deciphera for $2.4B, X4’s FDA approval of XOLREMDI, and how COVID fatigue could be causing us to minimize the threat of the avian influenza H5N1. The group also discusses Biden’s Cancer Moonshot getting killed by Congress, a federal judge throws out two drugmaker IRA lawsuits and the FTC goes after drug company’s “junk” patents in obesity and other device combos. Adam sparks a group discussion around his exclusive STAT article on how an emerging safety issue in MorphoSys’ Phase 3 cancer study may complicate its acquisition by Novartis. Other topics covered this week include BridgeBio spinning out an oncology company as it focuses on the anticipated launch of its heart drug, US government moving to reclassify marijuana from schedule 1 to schedule 111 drug, and more. *This episode aired on May 3, 2024.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode